{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:31:28Z","timestamp":1793035888898,"version":"4.5.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"am","delay-in-days":359,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014480","name":"Horizon Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005630","name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Cardiologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005630","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.jbspin.2020.05.002","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T17:22:51Z","timestamp":1589563371000},"page":"395-404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"title":["2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8395-826X","authenticated-orcid":false,"given":"Tristan","family":"Pascart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1087-7768","authenticated-orcid":false,"given":"Augustin","family":"Latourte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9-Marc","family":"Flipo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0384-8587","authenticated-orcid":false,"given":"G\u00e9rard","family":"Chal\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Coblentz-Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Cohen-Solal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang-Korng","family":"Ea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Grichy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Letavernier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Liot\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Ottaviani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sigwalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Vandecandelaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2132-4074","authenticated-orcid":false,"given":"Pascal","family":"Richette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5080-4790","authenticated-orcid":false,"given":"Thomas","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2020.05.002_bib0450","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","article-title":"Gout","volume":"388","author":"Dalbeth","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0455","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1136\/annrheumdis-2019-215933","article-title":"Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout","volume":"78","author":"Bursill","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0460","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/acr.22660","article-title":"Prevalence of Gout in the Adult Population of France","volume":"68","author":"Bardin","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0465","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/annrheumdis-2013-203779","article-title":"Revisiting comorbidities in gout: a cluster analysis","volume":"74","author":"Richette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0470","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nrrheum.2014.124","article-title":"Improving cardiovascular and renal outcomes in gout: what should we target?","volume":"10","author":"Richette","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0475","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0480","first-page":"1447","article-title":"2012 American College of Rheumatology guidelines for management of gout","volume":"64","author":"Khanna","year":"2012","journal-title":"Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0485","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0490","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/kex521","article-title":"The British Society for Rheumatology Guideline for the Management of Gout","volume":"57","author":"Hui","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0495","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/M16-0570","article-title":"Clinical Guidelines Committee of the American College of P. Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0500","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrrheum.2017.126","article-title":"Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)","volume":"13","author":"Dalbeth","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0505","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jbspin.2017.04.002","article-title":"GOSPEL: 3 Management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century \u2013 comparison with 2006 EULAR Recommendations","volume":"84","author":"Goossens","year":"2017","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0510","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jbspin.2017.03.013","article-title":"Persistent clinical inertia in gout in 2014: An observational French longitudinal patient database study","volume":"85","author":"Maravic","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0515","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1093\/rheumatology\/kez203","article-title":"Difficult-to-treat gout flares: eligibility for interleukin-1 inhibition in private practice is uncommon according to current EMA approval","volume":"58","author":"Pascart","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2020.05.001","article-title":"et al., 2020 Recommendations from the French Society of Rheumatology for the management of gout: management of acute flares","author":"Latourte","year":"2020","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0525","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial","volume":"392","author":"Doherty","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0530","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","article-title":"Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study","volume":"72","author":"Rees","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0535","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0540","article-title":"Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in gout","author":"Bursill","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0545","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jbspin.2015.01.002","article-title":"Hyperuricemia starts at 360 micromoles (6mg\/dL)","volume":"82","author":"Bardin","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0550","first-page":"529","article-title":"Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care-5-year follow-up of a proof-of-concept study","volume":"56","author":"Abhishek","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0555","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/art.40929","article-title":"Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial","volume":"71","author":"Dalbeth","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0560","article-title":"Effects of conventional uric acid lowering therapy on monosodium urate crystal deposits","author":"Ellmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0565","doi-asserted-by":"crossref","first-page":"e017542","DOI":"10.1136\/bmjopen-2017-017542","article-title":"Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis","volume":"8","author":"Yin","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0570","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/rheumatology\/key155","article-title":"Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD)","volume":"57","author":"Scheepers","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0575","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0580","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-017-0890-9","article-title":"Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options","volume":"15","author":"Bardin","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0585","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kex530","article-title":"Key barriers to gout care: a systematic review and thematic synthesis of qualitative studies","author":"Rai","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0590","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/acr.23147","article-title":"Illness Perceptions and Mortality in Patients With Gout: A Prospective Observational Study","volume":"69","author":"Serlachius","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0595","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/annrheumdis-2014-206410","article-title":"Comorbidities in patients with gout prior to and following diagnosis: case-control study","volume":"75","author":"Kuo","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0600","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/bmj.39449.819271.BE","article-title":"Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study","volume":"336","author":"Choi","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0605","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/acr.23515","article-title":"Effects of a Dietary Approach to Stop Hypertension (DASH) Diet Intervention on Serum Uric Acid in African Americans With Hypertension","volume":"70","author":"Juraschek","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0610","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2012-202421","article-title":"Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout","volume":"73","author":"Perez-Ruiz","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0615","doi-asserted-by":"crossref","first-page":"e001015","DOI":"10.1136\/rmdopen-2019-001015","article-title":"Failure to reach uric acid target of<0.36mmol\/l in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality","volume":"5","author":"Perez Ruiz","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0620","doi-asserted-by":"crossref","first-page":"e009328","DOI":"10.1161\/JAHA.118.009328","article-title":"Association of Gout With Long-Term Cardiovascular Outcomes Among Patients With Obstructive Coronary Artery Disease","volume":"7","author":"Pagidipati","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0625","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13075-018-1714-9","article-title":"Monosodium urate burden assessed with dual-energy computed tomography predicts the risk of flares in gout: a 12-month observational study: MSU burden and risk of gout flare","volume":"20","author":"Pascart","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0630","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/annrheumdis-2017-212046","article-title":"Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol","volume":"77","author":"Dalbeth","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0635","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3899\/jrheum.170199","article-title":"The Cost-effectiveness of Biannual Serum Urate (SU) Monitoring after Reaching Target in Gout: A Health Economic Analysis Comparing SU Monitoring","volume":"45","author":"Robinson","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0640","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrrheum.2015.132","article-title":"Allopurinol hypersensitivity: investigating the cause and minimizing the risk","volume":"12","author":"Stamp","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0645","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0650","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","article-title":"Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment","volume":"63","author":"Stamp","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0655","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jbspin.2016.09.020","article-title":"Efficacy and safety of febuxostat in 73 gouty patients with stage 4\/5 chronic kidney disease: a retrospective study of 10 centers","volume":"84","author":"Juge","year":"2017","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0660","article-title":"Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis","author":"Kim","year":"2019","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0665","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0670","article-title":"Discontinuing febuxostat might cause more deaths than continuing febuxostat: the untold story from the CARES trial","author":"Ghang","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0675","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","article-title":"A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0680","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1136\/annrheumdis-2017-211873","article-title":"Allopurinol dose escalation to achieve serum urate below 6mg\/dL: an open-label extension study","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0685","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2017-211574","article-title":"Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study","volume":"77","author":"Yamanaka","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0690","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0695","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1093\/oxfordjournals.ndt.a027096","article-title":"Colchicine toxicity in patients with chronic renal failure","volume":"11","author":"Montseny","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0700","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/art.30389","article-title":"Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4\/P-glycoprotein inhibitors","volume":"63","author":"Terkeltaub","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0705","doi-asserted-by":"crossref","first-page":"684","DOI":"10.2174\/1381612824999180115103951","article-title":"Colchicine in Gout: An Update","volume":"24","author":"Pascart","year":"2018","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0710","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/rheumatology\/key229","article-title":"Genetic association between adiposity and gout: a Mendelian randomization study","volume":"57","author":"Larsson","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0715","doi-asserted-by":"crossref","first-page":"e1002937","DOI":"10.1371\/journal.pmed.1002937","article-title":"Genetically determined serum urate levels and cardiovascular and other diseases in UK Biobank cohort: A phenome-wide mendelian randomization study","volume":"16","author":"Li","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0720","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jphs.2017.11.011","article-title":"The uricosuric effects of dihydropyridine calcium channel blockers in vivo using urate under-excretion animal models","volume":"136","author":"Hori","year":"2018","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0725","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S2213-8587(18)30029-9","article-title":"Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study","volume":"6","author":"Waldman","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0730","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/rheumatology\/kex065","article-title":"Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis","volume":"56","author":"Zhang","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0735","doi-asserted-by":"crossref","first-page":"e031550","DOI":"10.1136\/bmjopen-2019-031550","article-title":"Gout and the risk of advanced chronic kidney disease in the UK health system: a national cohort study","volume":"9","author":"Stack","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0740","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1186\/ar4281","article-title":"Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR)","volume":"15","author":"Scire","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0745","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2017.12.005","article-title":"Health-related quality of life in gout in primary care: Baseline findings from a cohort study","volume":"48","author":"Chandratre","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0750","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3899\/jrheum.071229","article-title":"Quality of life and disability in patients with treatment-failure gout","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0755","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1136\/annrheumdis-2012-201687","article-title":"Gout: why is this curable disease so seldom cured?","volume":"71","author":"Doherty","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0760","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1592\/phco.28.4.437","article-title":"Comparison of drug adherence rates among patients with seven different medical conditions","volume":"28","author":"Briesacher","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0765","article-title":"Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)","author":"Bardin","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0770","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/RHU.0000000000000235","article-title":"Does starting allopurinol prolong acute treated gout? A randomized clinical trial","volume":"21","author":"Hill","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0775","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/annrheumdis-2016-209467","article-title":"Treat-to-target (T2T) recommendations for gout","volume":"76","author":"Kiltz","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0780","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/art.40233","article-title":"Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0785","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0790","article-title":"Ultrasound evaluation in follow-up of urate-lowering therapy in gout: the USEFUL study","author":"Ebstein","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0795","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/aje\/kwm127","article-title":"Plasma urate and risk of Parkinson's disease","volume":"166","author":"Weisskopf","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0800","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ana.24281","article-title":"Mendelian randomization of serum urate and parkinson disease progression","volume":"76","author":"Simon","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0805","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/ana.25294","article-title":"collaborators I, et al. Mendelian randomization study shows no causal relationship between circulating urate levels and Parkinson's disease","volume":"84","author":"Kia","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0810","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/annrheumdis-2013-203226","article-title":"Managing gout needs more than drugs: \u201cIl faut le savoir-faire, l\u2019Art et la maniere\u201d","volume":"72","author":"Liote","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0815","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0820","first-page":"630","article-title":"Characteristics and management of gout patients in Europe: data from a large cohort of patients","volume":"19","author":"Richette","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0825","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1136\/annrheumdis-2015-207984","article-title":"Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims","volume":"75","author":"Solomon","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0830","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3899\/jrheum.111533","article-title":"Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout","volume":"39","author":"Crittenden","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0835","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1345\/aph.1H064","article-title":"Rhabdomyolysis in a patient treated with colchicine and atorvastatin","volume":"40","author":"Tufan","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0840","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s40261-013-0168-8","article-title":"Effect of steady-state atorvastatin on the pharmacokinetics of a single dose of colchicine in healthy adults under fasted conditions","volume":"34","author":"Davis","year":"2014","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0845","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/ard.2010.144063","article-title":"Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study","volume":"70","author":"Schlesinger","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0850","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/annrheumdis-2016-210588","article-title":"The unclosing premature mortality gap in gout: a general population-based study","volume":"76","author":"Fisher","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0855","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s40265-016-0591-2","article-title":"Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis","volume":"76","author":"Derosa","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0860","first-page":"d8190","article-title":"Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BM","volume":"344","author":"Choi","year":"2012","journal-title":"J"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0865","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/ajh.2008.245","article-title":"Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients","volume":"21","author":"Hamada","year":"2008","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0870","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.semarthrit.2014.10.008","article-title":"The effect of initiating pharmacologic insulin on serum uric acid levels in patients with diabetes: a matched cohort analysis","volume":"44","author":"MacFarlane","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0875","doi-asserted-by":"crossref","first-page":"F826","DOI":"10.1152\/ajprenal.00012.2017","article-title":"Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2","volume":"313","author":"Toyoki","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0880","first-page":"44","article-title":"[Use of metformin (siofor) in patients with gout and insulin resistance (pilot 6-month results)]","volume":"77","author":"Barskova","year":"2005","journal-title":"Ter Arkh"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0885","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1136\/annrheumdis-2018-214656","article-title":"mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy?","volume":"78","author":"Vazirpanah","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.002_bib0890","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2147\/TCRM.S112236","article-title":"An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients","volume":"12","author":"Wang","year":"2016","journal-title":"Ther Clin Risk Manag"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X20300853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X20300853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:26:17Z","timestamp":1761150377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X20300853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":89,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1297319X20300853"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2020.05.002","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2020.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie.","name":"copyright","label":"Copyright"}]}}